title: Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup.
authors.affiliation: a Wilhelminen Cancer Research Institute, Wilhelminenspital , Vienna , Austria.
authors.forename: Heinz
authors.initials: H
authors.lastname: Ludwig
authors.affiliation: b School of Medicine, National and Kapodistrian University of Athens , Athens , Greece.
authors.forename: Meletios A
authors.initials: MA
authors.lastname: Dimopoulos
authors.affiliation: c University of Nantes , Nantes , France.
authors.forename: Philippe
authors.initials: P
authors.lastname: Moreau
authors.affiliation: d National University Cancer Institute, Singapore.|e National University Health System, Singapore.|f Cancer Science Institute, Singapore.|g National University of Singapore , Singapore.
authors.forename: Wee-Joo
authors.initials: WJ
authors.lastname: Chng
authors.affiliation: h Heidelberg Medical University , Heidelberg , Germany.
authors.forename: Hartmut
authors.initials: H
authors.lastname: Goldschmidt
authors.affiliation: i University Hospital Ostrava and Faculty of Medicine, University of Ostrava , Ostrava , Czech Republic.
authors.forename: Roman
authors.initials: R
authors.lastname: Hájek
authors.affiliation: j CHRU Lille Hôpital Claude Huriez , Lille , France.
authors.forename: Thierry
authors.initials: T
authors.lastname: Facon
authors.affiliation: k University Hospital Brno , Brno , Czech Republic.
authors.forename: Ludek
authors.initials: L
authors.lastname: Pour
authors.affiliation: l Weill Cornell Medical College/New York Presbyterian Hospital , New York , NY , USA.
authors.forename: Ruben
authors.initials: R
authors.lastname: Niesvizky
authors.affiliation: m Institut Català d'Oncologia, Institut Josep Carreras, Hospital Germans Trias i Pujol , Barcelona , Spain.
authors.forename: Albert
authors.initials: A
authors.lastname: Oriol
authors.affiliation: n Hospital Clínic de Barcelona , Barcelona , Spain.
authors.forename: Laura
authors.initials: L
authors.lastname: Rosiñol
authors.affiliation: o First Republican Clinical Hospital of Udmurtia , Izhevsk , Russia.
authors.forename: Aleksandr
authors.initials: A
authors.lastname: Suvorov
authors.affiliation: p Department of Translational Medicine , University of Eastern Piedmont , Novara , Italy.
authors.forename: Gianluca
authors.initials: G
authors.lastname: Gaidano
authors.affiliation: q University Hospital Olomouc , Olomouc , Czech Republic.
authors.forename: Tomas
authors.initials: T
authors.lastname: Pika
authors.affiliation: r Universitatsklinikum Tubingen , Tubingen , Germany.
authors.forename: Katja
authors.initials: K
authors.lastname: Weisel
authors.affiliation: s University Multiprofile Hospital for Active Treatment "Sv. Georgi" and Medical University , Plovdiv , Bulgaria.
authors.forename: Vesselina
authors.initials: V
authors.lastname: Goranova-Marinova
authors.affiliation: t University of Torino , Torino , Italy.
authors.forename: Antonio
authors.initials: A
authors.lastname: Palumbo
authors.affiliation: u Onyx Pharmaceuticals, Inc, an Amgen subsidiary , South San Francisco , CA , USA.
authors.forename: Heidi H
authors.initials: HH
authors.lastname: Gillenwater
authors.affiliation: u Onyx Pharmaceuticals, Inc, an Amgen subsidiary , South San Francisco , CA , USA.
authors.forename: Nehal
authors.initials: N
authors.lastname: Mohamed
authors.affiliation: u Onyx Pharmaceuticals, Inc, an Amgen subsidiary , South San Francisco , CA , USA.
authors.forename: Sanjay
authors.initials: S
authors.lastname: Aggarwal
authors.affiliation: u Onyx Pharmaceuticals, Inc, an Amgen subsidiary , South San Francisco , CA , USA.
authors.forename: Shibao
authors.initials: S
authors.lastname: Feng
authors.affiliation: v Royal Prince Alfred Hospital , Camperdown , New South Wales , Australia.
authors.forename: Douglas
authors.initials: D
authors.lastname: Joshua
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000069286:Bortezomib / Q000008:administration & dosage; D003907:Dexamethasone / Q000008:administration & dosage; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000473:pathology; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy* / Q000473:pathology; D009842:Oligopeptides / Q000008:administration & dosage; D011379:Prognosis; D015996:Survival Rate
chemical_list: D009842:Oligopeptides; D000069286:Bortezomib; C524865:carfilzomib; D003907:Dexamethasone